STOCK TITAN

Intellia Therapeutics, Inc - NTLA STOCK NEWS

Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering clinical-stage gene editing company dedicated to revolutionizing medicine through the use of CRISPR-based therapies. Founded in 2014 by Caribou Biosciences and Atlas Venture, along with leading scientists in the field, Intellia harnesses the potential of CRISPR/Cas9 technology to develop curative treatments for a variety of genetically defined diseases.

The company's core mission is to leverage CRISPR/Cas9—an innovative technology adapted from a natural cellular process that allows for precise and flexible gene editing. This technology enables the correction of specific DNA sequences within any organism, opening new frontiers in biomedical research and clinical interventions.

Intellia's portfolio includes both in vivo and ex vivo gene editing programs. The in vivo programs aim to edit disease-causing genes directly within the human body, targeting conditions such as ATTR amyloidosis, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Notable achievements include the interim results from their NTLA-2002 program for HAE, which showed a 95% reduction in monthly attack rates, with most patients remaining attack-free.

The ex vivo programs focus on engineering human cells outside the body to treat cancer and autoimmune diseases. These programs include collaborations with prominent companies like Regeneron and Novartis, which help advance their therapeutic pipeline.

Intellia's financial condition reflects its robust pipeline and strategic partnerships. The company recently reported strong enrollment progress in their pivotal Phase 3 MAGNITUDE trial for NTLA-2001 targeted at ATTR amyloidosis with cardiomyopathy. They have also formed a strategic collaboration with ReCode Therapeutics to develop treatments for cystic fibrosis, utilizing ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform.

Committed to advancing the field of gene editing, Intellia continues to expand its CRISPR-based platform with novel editing and delivery technologies. The company remains at the forefront of a new era in medicine, as evidenced by its ongoing clinical trials and promising preliminary data.

For more detailed information and the latest updates, investors and stakeholders are encouraged to visit www.intelliatx.com and follow Intellia on Twitter @intelliatx.

Rhea-AI Summary
Intellia Therapeutics, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced its strategic priorities through 2026 and key anticipated 2024 milestones. The company ended 2023 in a strong financial position with approximately $1.0 billion in cash and is on track to dose the first patient in the pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024. Intellia aims to transform the lives of patients and bring forth a new era in medicine by advancing its pipeline and platform innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
none
-
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced that the European Commission has granted orphan drug designation to NTLA-2002, an in vivo CRISPR-based investigational therapy for the treatment of hereditary angioedema (HAE). The orphan drug designation provides regulatory, financial, and commercial incentives to develop therapies for rare diseases. Intellia has received five special regulatory designations for NTLA-2002, indicating significant progress in the development of potential one-time treatment for people with HAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.09%
Tags
-
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received FDA clearance for NTLA-2001, the first in vivo CRISPR candidate to enter late-stage clinical development. The company plans to initiate the MAGNITUDE pivotal Phase 3 trial for patients with ATTR amyloidosis with cardiomyopathy by year-end. Clinical data showed consistent, deep, and durable serum TTR reduction after a single dose of NTLA-2001, with over 90% median serum TTR reduction. The company also reported a strong financial position with $992.5 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.27%
Tags
Rhea-AI Summary
Intellia Therapeutics presents positive interim results from its Phase 1 study of NTLA-2001, an investigational CRISPR-based therapy for ATTR amyloidosis. The study shows consistent and deep reductions in serum TTR levels with a single dose of NTLA-2001. The 55 mg dose has been selected for further evaluation in a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
-
Rhea-AI Summary
Intellia Therapeutics announces upcoming events in November: presentation of NTLA-2001 clinical data at the 4th International ATTR Amyloidosis Meeting and Q3 earnings webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
conferences earnings clinical trial
-
Rhea-AI Summary
Intellia Therapeutics receives FDA clearance for NTLA-2001 gene editing therapy for ATTR amyloidosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
Rhea-AI Summary
Intellia Therapeutics Receives PRIME Designation for NTLA-2002 in the Treatment of Hereditary Angioedema
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Summary
Regeneron and Intellia expand collaboration to develop CRISPR-based gene editing therapies for neurological and muscular diseases. Collaboration combines Intellia's genome editing platform with Regeneron's viral vector delivery technologies. Companies will initially research two non-liver targets. Each company has the opportunity to lead development and commercialization for one target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
Rhea-AI Summary
Intellia Therapeutics reports operational highlights and financial results for Q2 2023. They have completed patient identification for Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) and plan to initiate Phase 3 study in Q3 2024. They also plan to submit IND application for NTLA-2001 for ATTR amyloidosis and present additional clinical data in 2023. They expect to submit CTA for NTLA-3001 for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. They ended Q2 2023 with $1.1 billion in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) to present Q2 2023 financial results and operational highlights on August 3, 2023. Join the conference call for insights into the company's progress and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags

FAQ

What is the current stock price of Intellia Therapeutics (NTLA)?

The current stock price of Intellia Therapeutics (NTLA) is $12.18 as of December 20, 2024.

What is the market cap of Intellia Therapeutics (NTLA)?

The market cap of Intellia Therapeutics (NTLA) is approximately 1.3B.

What is the mission of Intellia Therapeutics?

Intellia Therapeutics aims to develop curative medicines using CRISPR/Cas9 gene editing technology.

What diseases is Intellia targeting with their CRISPR-based therapies?

Intellia targets genetically defined diseases such as ATTR amyloidosis, hereditary angioedema (HAE), sickle cell disease, and cystic fibrosis.

What are Intellia's key advancements in hereditary angioedema (HAE) treatment?

Intellia's NTLA-2002 program for HAE has shown a 95% reduction in monthly attack rates, with most patients remaining attack-free.

When was Intellia Therapeutics founded?

Intellia Therapeutics was founded in 2014.

Who are Intellia's key collaborators?

Intellia has collaborations with Regeneron, Novartis, and ReCode Therapeutics.

What is CRISPR/Cas9?

CRISPR/Cas9 is a gene editing technology that allows for precise modification of DNA sequences, adapted from a natural cellular process.

How does Intellia's in vivo program work?

Intellia's in vivo programs use CRISPR to edit disease-causing genes directly inside the human body.

What are the recent financial highlights of Intellia Therapeutics?

Intellia recently reported strong enrollment progress in their Phase 3 MAGNITUDE trial for NTLA-2001.

What is the scope of Intellia's collaboration with ReCode Therapeutics?

The collaboration aims to develop genomic medicines for cystic fibrosis using Intellia's CRISPR-based platform and ReCode's SORT LNP delivery platform.

Where can I find more information about Intellia Therapeutics?

Visit Intellia's website at www.intelliatx.com and follow them on Twitter @intelliatx.

Intellia Therapeutics, Inc

Nasdaq:NTLA

NTLA Rankings

NTLA Stock Data

1.26B
100.15M
1.21%
91.4%
16.07%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
CAMBRIDGE